{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T06:06:55Z","timestamp":1783490815920,"version":"3.55.0"},"reference-count":34,"publisher":"Public Library of Science (PLoS)","issue":"1","license":[{"start":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T00:00:00Z","timestamp":1325808000000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/publicdomain\/zero\/1.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0029941","type":"journal-article","created":{"date-parts":[[2012,1,6]],"date-time":"2012-01-06T22:04:12Z","timestamp":1325887452000},"page":"e29941","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":89,"title":["A Novel Strategy for Development of Recombinant Antitoxin Therapeutics Tested in a Mouse Botulism Model"],"prefix":"10.1371","volume":"7","author":[{"given":"Jean","family":"Mukherjee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacqueline M.","family":"Tremblay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clinton E.","family":"Leysath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kwasi","family":"Ofori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Baldwin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochuan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniela","family":"Bedenice","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert P.","family":"Webb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick M.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard A.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul","family":"Tzipori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles B.","family":"Shoemaker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2012,1,6]]},"reference":[{"key":"ref1","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/nrmicro977","article-title":"Antitoxins: novel strategies to target agents of bioterrorism.","volume":"2","author":"GJ Rainey","year":"2004","journal-title":"Nature reviews Microbiology"},{"key":"ref2","doi-asserted-by":"crossref","first-page":"833","DOI":"10.3201\/eid0808.010516","article-title":"Passive antibody administration (immediate immunity) as a specific defense against biological weapons.","volume":"8","author":"A Casadevall","year":"2002","journal-title":"Emerg Infect Dis"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"11346","DOI":"10.1073\/pnas.172229899","article-title":"Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody.","volume":"99","author":"A Nowakowski","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1128\/IAI.70.2.612-619.2002","article-title":"Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection.","volume":"70","author":"J Mukherjee","year":"2002","journal-title":"Infect Immun"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1128\/IAI.73.2.795-802.2005","article-title":"A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge.","volume":"73","author":"N Mohamed","year":"2005","journal-title":"Infect Immun"},{"key":"ref6","first-page":"743","article-title":"Interscience Conference on Antimicrobial Agents and Chemotherapy - 50th Annual Meeting - Research on Promising New Agents: Part 1.","volume":"13","author":"K Walker","year":"2010","journal-title":"IDrugs"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1146\/annurev.immunol.15.1.203","article-title":"Fc receptor biology.","volume":"15","author":"M Daeron","year":"1997","journal-title":"Annu Rev Immunol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1002\/art.10189","article-title":"Defective Fc-dependent processing of immune complexes in patients with systemic lupus erythematosus.","volume":"46","author":"KA Davies","year":"2002","journal-title":"Arthritis Rheum"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.510240128","article-title":"Liver cell uptake and degradation of soluble immunoglobulin G immune complexes in vivo and in vitro in rats.","volume":"24","author":"AG Johansson","year":"1996","journal-title":"Hepatology"},{"issue":"Pt 18","key":"ref10","doi-asserted-by":"crossref","first-page":"3255","DOI":"10.1242\/jcs.113.18.3255","article-title":"Fc receptor mediated endocytosis of small soluble immunoglobulin G immune complexes in Kupffer and endothelial cells from rat liver.","volume":"113","author":"T Lovdal","year":"2000","journal-title":"J Cell Sci"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1056\/NEJMoa051926","article-title":"Human botulism immune globulin for the treatment of infant botulism.","volume":"354","author":"SS Arnon","year":"2006","journal-title":"N Engl J Med"},{"key":"ref12","first-page":"299","article-title":"Investigational heptavalent botulinum antitoxin (HBAT) to replace licensed botulinum antitoxin AB and investigational botulinum antitoxin E.","volume":"59","year":"2010","journal-title":"MMWR Morbidity and mortality weekly report"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1086\/444507","article-title":"Botulism.","volume":"41","author":"J Sobel","year":"2005","journal-title":"Clinical infectious diseases : an official publication of the Infectious Diseases Society of America"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1128\/IAI.69.1.570-574.2001","article-title":"High-affinity, protective antibodies to the binding domain of botulinum neurotoxin type A.","volume":"69","author":"DD Pless","year":"2001","journal-title":"Infect Immun"},{"key":"ref15","article-title":"Domain-based assays of individual antibody concentrations in an oligoclonal combination targeting a single protein.","author":"Q Meng","year":"2011","journal-title":"Anal Biochem"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"e3023","DOI":"10.1371\/journal.pone.0003023","article-title":"Neutralization of botulinum neurotoxin by a human monoclonal antibody specific for the catalytic light chain.","volume":"3","author":"SP Adekar","year":"2008","journal-title":"PLoS ONE"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"e12416","DOI":"10.1371\/journal.pone.0012416","article-title":"Characterization of botulinum neurotoxin type A neutralizing monoclonal antibodies and influence of their half-lives on therapeutic activity.","volume":"5","author":"C Mazuet","year":"2010","journal-title":"PLoS ONE"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1128\/IAI.01084-09","article-title":"Efficient serum clearance of botulinum neurotoxin achieved using a pool of small antitoxin binding agents.","volume":"78","author":"J Sepulveda","year":"2010","journal-title":"Infect Immun"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/S0167-4838(99)00030-8","article-title":"Comparison of physical chemical properties of llama VHH antibody fragments and mouse monoclonal antibodies.","volume":"1431","author":"RH van der Linden","year":"1999","journal-title":"Biochim Biophys Acta"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1110\/ps.34602","article-title":"Single-domain antibody fragments with high conformational stability.","volume":"11","author":"M Dumoulin","year":"2002","journal-title":"Protein Sci"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1093\/emboj\/17.13.3512","article-title":"Potent enzyme inhibitors derived from dromedary heavy-chain antibodies.","volume":"17","author":"M Lauwereys","year":"1998","journal-title":"Embo J"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1038\/scientificamerican0805-78","article-title":"Nanobodies.","volume":"293","author":"WW Gibbs","year":"2005","journal-title":"Sci Am"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/08820139.2010.542228","article-title":"Nanobody; an old concept and new vehicle for immunotargeting.","volume":"40","author":"F Rahbarizadeh","year":"2011","journal-title":"Immunological investigations"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/S1380-2933(97)00067-5","article-title":"New protein engineering approaches to multivalent and bispecific antibody fragments.","volume":"3","author":"A Pluckthun","year":"1997","journal-title":"Immunotechnology : an international journal of immunological engineering"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"4305","DOI":"10.1128\/IAI.00405-09","article-title":"Antibody protection against botulinum neurotoxin intoxication in mice.","volume":"77","author":"LW Cheng","year":"2009","journal-title":"Infect Immun"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"3273","DOI":"10.1074\/jbc.M806889200","article-title":"General strategy to humanize a camelid single-domain antibody and identification of a universal humanized nanobody scaffold.","volume":"284","author":"C Vincke","year":"2009","journal-title":"J Biol Chem"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.tibtech.2005.07.007","article-title":"Artificial, non-antibody binding proteins for pharmaceutical and industrial applications.","volume":"23","author":"T Hey","year":"2005","journal-title":"Trends Biotechnol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"4490","DOI":"10.1016\/j.vaccine.2009.05.030","article-title":"Production of catalytically inactive BoNT\/A1 holoprotein and comparison with BoNT\/A1 subunit vaccines against toxin subtypes A1, A2, and A3.","volume":"27","author":"RP Webb","year":"2009","journal-title":"Vaccine"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.ijpara.2007.02.005","article-title":"Three surface antigens dominate the mucosal antibody response to gastrointestinal L3-stage strongylid nematodes in field immune sheep.","volume":"37","author":"DR Maass","year":"2007","journal-title":"Int J Parasitol"},{"issue":"6","key":"ref30","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.toxicon.2010.07.003","article-title":"Camelid single domain antibodies (VHHs) as neuronal cell intrabody binding agents and inhibitors of Clostridium botulinum neurotoxin (BoNT) proteases.","volume":"56","author":"JM Tremblay","year":"2010","journal-title":"Toxicon"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1159\/000112485","article-title":"A procedure for purifying neuron-like cells in cultures from central nervous tissue with a defined medium.","volume":"2","author":"SD Skaper","year":"1979","journal-title":"Dev Neurosci"},{"issue":"6","key":"ref32","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1021\/ml100074s","article-title":"Identification of a Natural Product Antagonist against the Botulinum Neurotoxin Light Chain Protease.","volume":"1","author":"LM Eubanks","year":"2010","journal-title":"ACS Med Chem Lett"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1006\/taap.1994.1181","article-title":"Measurement of botulinum toxin activity: evaluation of the lethality assay.","volume":"128","author":"LB Pearce","year":"1994","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.jim.2007.04.008","article-title":"Alpaca (Lama pacos) as a convenient source of recombinant camelid heavy chain antibodies (VHHs).","volume":"324","author":"DR Maass","year":"2007","journal-title":"J Immunol Methods"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0029941","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,18]],"date-time":"2025-03-18T15:37:11Z","timestamp":1742312231000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0029941"}},"subtitle":[],"editor":[{"given":"Eric A.","family":"Johnson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2012,1,6]]},"references-count":34,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,1,6]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0029941","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,6]]}}}